From advice to observations, these five quotes overheard at SXSW proves Houston had some great spokespeople at the 2019 SXSW Interactive festival. Photos courtesy

Houston had no shortage of representatives at the 2019 SXSW Interactive festival, which took place March 8 to 12 in Austin. Several sat on panels, lead mixers, or even starred in a movie for the film track of the conference.

I had the pleasure of sitting in on a great deal of these events featuring the best and the brightest of Houston's innovation stars, but I realize most did not. To catch you up and rid you of your fear of missing out, check out these five overheard quotes from the fest.

"I think it's so important to find your focus and know what to say no to, because you can't do it all. Elizabeth [Gore] and I have a monthly 'meeting of no' where we literally check off things off our plate that we need to stop doing because we just don't have enough time. It's probably one of our most valuable hours."

Carolyn Rodz, co-founded Alice with Elizabeth Gore. Alice co-hosted a series of panels at the Bumble Hive. She was asked, during the investment-focused panel, about focusing on B-to-B vs. B-to-C as a startup. Alice and Bumble just recently announced a partnership.

"We're trying to awaken the sleeping giant — a really huge city with lots of money, trying to infiltrate and activate huge family offices and rally people behind the goal of building a vibrant startup community. We've got a long way to go in terms of attracting VC talent — we're still behind Austin and Dallas."

Lawson Gow, founder and CEO of The Cannon, at the Austinpreneur podcast recording of "The Texas Startup Manifesto" episode. He was asked about what he's been trying to accomplish at The Cannon. Gow is the son of InnovationMap's parent company's CEO.

"We've got all the basic tools, and we know what the main issues are. There's still a lot to do, but we need to be smart and do fact-based and mechanism-based combinations."

James Allison, chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson Cancer Center. At his panel, "Making the Fight Against Cancer Even More Personal," he was asked about the current status of immunotherapy research.

“Have very specific questions. I hate the ‘can I pick your brain’ request. If you want advice on something, ask me that specifically. And, show up at everything. … It’s not about what network you have, but how many networks you can get into.”

Grace Rodriguez, CEO and executive director of Impact Hub Houston. On the "Equitable Growth Ecosystems for Entrepreneurs" panel, she was asked about how an entrepreneur might try to grow their network and mentorship.

"Houston is an incredibly industrial town. We have more Fortune 500 companies here than anywhere other than New York — most of them in the world of the dirty and dangerous. We don't have a lot of scooter companies."

Gabriella Rowe, CEO of Station Houston. She was asked while on her panel, "Startup Funding: From Apprenticeships to Professions," about bootstrapping as a startup. Read more about this discussion here.

Houston, we have a problem — and it's helping local startups have access to funding. Photo by Zview/Getty Images

SXSW panelists: Improving access to funding is key for Houston's continued ecosystem growth

Show me the money

A few weeks ago, Mayor of Houston Sylvester Turner and Station Houston CEO Gabriella Rowe proclaimed that Houston's up-and-coming innovation ecosystem was no longer up and coming: It had arrived. But what preceded that proclamation was years of figuring out what it was Houston could do to get to this point.

"We're the fourth largest city in the United States, and in 2015 were ranked 20th out of 25 ecosystems," Rowe says at a panel at the 2019 SXSW Interactive festival.

Following that shocking news, Rowe says the city's focus was on building tools — accelerators, incubators, education — but nowhere did anyone talk about funding. Now, years later, with plenty of accelerators, workspaces, and educational programs, Rowe says Houston now has a great pipeline of companies, but the problem is finding funding for them to tap into.

Entrepreneurs are looking for three things when it comes to finding ways to fund their companies, according to Rowe. They want it to be accessible capital — not something they have to take a class on to figure out how to get to it. They also want it to be impactful and local to where their headquarters is.

"When I think about accessible, impactful, and local, I think, well, not a lot falls into that category [in Houston]," Rowe says. "We're not doing it particularly well right now."

It's a structural problem, according to Rowe. While the city has built up its entrepreneurial climate, it hasn't yet made the same effort with investors.

"Even if we have one or two funds, we need an ecosystem that supports funding in the same way we have an ecosystem that supports entrepreneurs," she says.

Joe Milam, founder of Austin-based AngelSpan, an early stage investor relations platform, says the issue in Houston — and Austin — is that industries can be siloed. There's a huge need for an honest broker to connect the dots across the city, and that person needs to be impartial.

"You gotta care about your community first, before you care about your own agenda," Milam says. "Otherwise, you're going to flounder like Houston has, and how Austin still does."

One thing everyone agreed on during the Saturday, March 9, panel was that Houston has a lot of money, but it's been sitting on the sidelines. The mission is, in addition to bringing in venture capital firms, finding ways to engage money that's already in town.

"We have to produce tools to enable that capital that's hiding," Rowe says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”